Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 1981;21(3):169-72.
doi: 10.1007/BF00627915.

Clinical pharmacology of tolmesoxide in refractory heart failure

C P O'Boyle, K McGarry, D Fitzgerald, J G Kelly, J Horgan, K O'Malley

Clinical pharmacology of tolmesoxide in refractory heart failure

C P O'Boyle et al. Eur J Clin Pharmacol. 1981.

Abstract

The haemodynamic effects and pharmacokinetics of single intravenous doses of tolmesoxide, a new vasodilator agent, were studied in 6 patients with severe cardiac failure secondary to ischaemic cardiomyopathy and refractory to conventional therapy. The mean (+ SEM) baseline cardiac index (CI) and pulmonary artery diastolic pressure (PADP) were 1.7 +0.11/min/m2 and 30.5 +4.1 mm Hg respectively. The mean % rise in CI was 78.8 +23.3 and the mean % fall in PADP was 35.2 +5.2. The mean half life of tolmesoxide in these patients was markedly prolonged at 15.6 +6.6h. Side effects were minimal - vomiting was seen in 1 patient. This agent warrants further study in the long term management of refractory cardiac failure.

PubMed Disclaimer

References

    1. Br Heart J. 1977 Jul;39(7):706-20 - PubMed
    1. Ann Intern Med. 1977 Apr;86(4):388-93 - PubMed
    1. N Engl J Med. 1974 Sep 19;291(12):587-92 - PubMed
    1. N Engl J Med. 1977 Jul 7;297(1):27-31 - PubMed
    1. Br J Pharmacol. 1978 May;63(1):111-8 - PubMed

LinkOut - more resources